Durvalumab Long-Term Safety and Efficacy Study
Public ClinicalTrials.gov record NCT04078152. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label, Multi-Center, Global Study to Evaluate Long Term Safety and Efficacy in Patients Who Are Receiving or Who Previously Received Durvalumab in Other Protocols (WAVE)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The aims of the study are to monitor the long-term safety of durvalumab, to provide continued treatment or retreatment with durvalumab to eligible patients, and to collect overall survival (OS) information.
Study identification
- NCT ID
- NCT04078152
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 163 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 130 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 5, 2019 (Actual)
- Primary completion
- Oct 31, 2022 (Actual)
- Completion
- Oct 31, 2024 (Actual)
- Last update posted
- Dec 20, 2024
2019 – 2024
United States locations
- U.S. sites
- 12
- U.S. states
- 11
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Fullerton | California | 92835 | — |
| Research Site | Washington D.C. | District of Columbia | 20007 | — |
| Research Site | Augusta | Georgia | 30912 | — |
| Research Site | Baltimore | Maryland | 21201 | — |
| Research Site | Minneapolis | Minnesota | 55407 | — |
| Research Site | St Louis | Missouri | 63110 | — |
| Research Site | Mineola | New York | 11501 | — |
| Research Site | Chapel Hill | North Carolina | 27514 | — |
| Research Site | Huntersville | North Carolina | 28078 | — |
| Research Site | Greenville | South Carolina | 29605 | — |
| Research Site | Nashville | Tennessee | 37203 | — |
| Research Site | Dallas | Texas | 75251 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 104 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04078152, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 20, 2024 · Synced Nov 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04078152 live on ClinicalTrials.gov.